RESEARCH-USE BIOSIMILAR ANTIBODY
Letolizumab
Antibody fragment · IgG1
Letolizumab (BMS-986004) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time.
TARGETCD40LG
YAntibody fragment
CATALOGSC-BS-430
CATALOG NUMBERSC-BS-430
MOLECULAR WEIGHTApprox. 78 kDa
PRODUCT FORMATAntibody fragment
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Letolizumab (BMS-986004) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time.
Letolizumab is a recombinant research-use antibody directed against CD40LG.